| Literature DB >> 23905901 |
Alan Rembach1, Tim M Ryan, Blaine R Roberts, James D Doecke, William J Wilson, Andrew D Watt, Kevin J Barnham, Colin L Masters.
Abstract
Alzheimer's disease (AD) is the most common cause of dementia in the elderly population and attempts to develop therapies have been unsuccessful because there is no means to target an effective therapeutic window. CNS biomarkers are insightful but impractical for high-throughput population-based screening. Therefore, a peripheral, blood-based biomarker for AD would significantly improve early diagnosis, potentially enable presymptomatic detection and facilitate effective targeting of disease-modifying treatments. The various constituents of blood, including plasma, platelets and cellular fractions, are now being systematically explored as a pool of putative peripheral biomarkers for AD. In this review we cover some less known peripheral biomarkers and highlight the latest developments for their clinical application.Entities:
Mesh：
Substances：
Year: 2013 PMID： 23905901 DOI： 10.2217/bmm.13.59
Source DB: PubMed Journal: Biomark Med ISSN： 1752-0363 Impact factor: 2.851